These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22431809)

  • 1. Effectiveness and safety of tigecycline: focus on use for approved indications.
    Vardakas KZ; Rafailidis PI; Falagas ME
    Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809
    [No Abstract]   [Full Text] [Related]  

  • 2. Tigecycline: benefits and risks.
    Cai Y; Wang R
    Lancet Infect Dis; 2011 Nov; 11(11):804-5. PubMed ID: 21784707
    [No Abstract]   [Full Text] [Related]  

  • 3. Tigecycline: an antibiotic for the twenty-first century.
    Dryden M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline: place in therapy and important considerations.
    Garrelts JC; Schroeder T
    Am J Health Syst Pharm; 2006 Jul; 63(13):1233. PubMed ID: 16790574
    [No Abstract]   [Full Text] [Related]  

  • 5. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label use of antibiotics in hospitalized patients: focus on tigecycline.
    Curcio D
    J Antimicrob Chemother; 2009 Dec; 64(6):1344-6. PubMed ID: 19759045
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

  • 8. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline for severe infections: the gap between the warning and the necessity.
    Curcio D
    J Antimicrob Chemother; 2011 Feb; 66(2):454-6. PubMed ID: 21115443
    [No Abstract]   [Full Text] [Related]  

  • 11. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates.
    Martín-Gandul C; García-Cabrera E; Castillo-Ojeda E; Jiménez-Mejías ME
    J Antimicrob Chemother; 2012 Apr; 67(4):1048-9. PubMed ID: 22207597
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment with the first glycylcycline--tigecycline].
    Musch A
    Med Monatsschr Pharm; 2006 May; 29(5):191-2. PubMed ID: 16719269
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bacterial resistance and a new antibiotic: tigecycline].
    Gobernado M
    Rev Esp Quimioter; 2006 Sep; 19(3):209-19. PubMed ID: 17099789
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
    Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What role for tigecycline in infections?
    BMJ Group
    Drug Ther Bull; 2008 Aug; 46(8):62-4. PubMed ID: 18687585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
    Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes.
    Conde-Estévez D; Grau S; Horcajada JP; Luque S
    Int J Antimicrob Agents; 2010 Nov; 36(5):471-2. PubMed ID: 20828992
    [No Abstract]   [Full Text] [Related]  

  • 18. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
    Johnson AP; Leibovici L
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
    [No Abstract]   [Full Text] [Related]  

  • 19. Tigecycline: a single antibiotic for polymicrobial infections.
    Pankey GA; Steele RW
    Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
    [No Abstract]   [Full Text] [Related]  

  • 20. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.